LakeShore Biopharma Co Ltd
LSB0.720USD
-0.017-2.28%
交易中 （美东）报价延迟15分钟
13.74M总市值
--市盈率 TTM
关于 LakeShore Biopharma Co Ltd 公司
LakeShore Biopharma Co Ltd（原名 YS Biopharma Co Ltd）是一家生物制药公司，致力于发现、开发、生产和商业化新一代传染病和癌症疫苗和治疗性生物制剂。公司的疫苗产品 YSJATM 狂犬病疫苗已实现商业化。公司还有四种处于不同临床开发阶段的候选产品，包括 PIKA 狂犬病疫苗、PIKA 重组 COVID-19 疫苗、PIKA YS-ON-001 和 PIKA YS-HBV-001，以及四种临床前阶段的候选产品，针对具有巨大医疗需求的 HBV、流感和癌症。此外，公司正在研究一系列处于发现阶段的治疗靶点、狂犬病和产品。
公司简介
公司代码LSB
公司名称LakeShore Biopharma Co Ltd
上市日期Jul 30, 2021
CEOMr. Dave Chenn
员工数量758
证券类型Ordinary Share
年结日Jul 30
公司地址- -
城市- -
上市交易所NASDAQ Capital Market Consolidated
国家- -
邮编- -
电话- -
网址- -
公司代码LSB
上市日期Jul 30, 2021
CEOMr. Dave Chenn
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
Mr. Gang Li
Mr. Gang Li
Head of Marketing and sales
Head of Marketing and sales
--
--
Dr. Stanley Yi Chang
Dr. Stanley Yi Chang
Independent Director
Independent Director
--
--
Dr. Ajit Shetty
Dr. Ajit Shetty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Thomas Xue
Mr. Thomas Xue
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Yi Zhang
Mr. Yi Zhang
Chairman of the Board
Chairman of the Board
4.91M
--
Mr. Dave Chenn
Mr. Dave Chenn
Interim Co-Chief Executive Officer, Director
Interim Co-Chief Executive Officer, Director
462.76K
--
Dr. Hui (David) Shao
Dr. Hui (David) Shao
President, Co-Chief Executive Officer, Director, Chief Business Officer
President, Co-Chief Executive Officer, Director, Chief Business Officer
313.64K
--
Ms. Chunyuan Wu
Ms. Chunyuan Wu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Zenaida Reynoso Mojares
Dr. Zenaida Reynoso Mojares
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chunyang Shao
Mr. Chunyang Shao
Director
Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
Crystal Peak Investment Inc
41.22%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
TD Securities, Inc.
2.54%
Shao (Hui)
0.76%
Other
19.70%
持股股东
持股股东
占比
Crystal Peak Investment Inc
41.22%
Apex Prospect Ltd
23.87%
Zhang (Yi)
11.91%
TD Securities, Inc.
2.54%
Shao (Hui)
0.76%
Other
19.70%
股东类型
持股股东
占比
Corporation
65.09%
Individual Investor
13.80%
Research Firm
2.54%
Investment Advisor
0.35%
Private Equity
0.34%
Investment Advisor/Hedge Fund
0.26%
Hedge Fund
0.03%
Other
17.60%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
28
16.97M
69.54%
+11.17M
2025Q1
32
16.97M
88.94%
+11.13M
2024Q4
63
15.91M
83.38%
+8.88M
2024Q3
69
15.84M
83.04%
+8.47M
2024Q2
74
16.03M
84.03%
+8.50M
2024Q1
78
15.49M
82.30%
+7.79M
2023Q4
79
6.05M
65.03%
-1.81M
2023Q3
78
6.62M
71.14%
+3.69M
2023Q2
76
6.62M
71.12%
+3.57M
2023Q1
71
6.78M
73.08%
+4.90M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Apex Prospect Ltd
9.84M
51.55%
+9.84M
--
Feb 08, 2024
Zhang (Yi)
4.91M
25.73%
--
--
Feb 16, 2024
TD Securities, Inc.
1.05M
5.49%
+1.05M
--
Mar 31, 2025
Shao (Hui)
313.64K
1.64%
+108.76K
+53.09%
Jun 30, 2024
OrbiMed Advisors, LLC
140.43K
0.74%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
116.51K
0.61%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
75.18K
0.39%
--
--
Mar 31, 2025
Superstring Capital Management LP
30.79K
0.16%
--
--
Mar 31, 2025
Barclays Bank PLC
24.76K
0.13%
--
--
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
公告日期
类型
比率
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
Sep 27, 2024
Merger
10<1
